Alzheimer's Disease: Selections from "The World Market for Neurotherapeutic Drugs" : Market Research Report

Alzheimer's Disease: Selections from "The World Market for Neurotherapeutic Drugs"

Published by: Kalorama Information

Published: Sep. 1, 2002 - 232 Pages

Special Offer. Now 25% off the original price of $1495.

Executive Summary

Background
Scope and Methodology
Size and Growth of Market
Market Trends

Overview of Neurologic Diseases and Disorders

Key Neurologic Diseases and Disorders
Alzheimer’s Disease

Treatment of Neurologic Diseases and Disorders

Alzheimer’s Disease
Antipsychotics
Anxiolytics
Antidepressants
Anticonvulsants

Progress and Promise in Therapeutics Development

Genetics and Neurogenomics
Neural Implant Technologies
Miscellaneous Advances
Vascular Endothelial Growth Factor (VEGF
Minocycline
Stroke and Apoptosis
Clinical Trial Activity

World Market Analysis

Background
The Markets by Geography
The United States
France
Germany
Italy
Spain
United Kingdom
Japan
The Market by Applications
Alzheimer’s Disease and Other Dementias

Company Profiles

Axonyx
Boston Life Sciences, Inc.
Centaur Pharmaceuticals, Inc.
Cephalon, Inc. Cortex Pharmaceuticals, Inc.
D-Pharm Ltd.
Elan Corporation plc
Guilford Pharmaceuticals Inc.
MitoKor Inc.
NeoTherapeutics, Inc.
NPS Pharmaceuticals, Inc.
Neurobiological Technologies, Inc.
Neurochem, Inc.
Neurocrine BioSciences, Inc.
Neurogen, Inc.
Shire Pharmaceuticals Group plc
Stem Cells Inc.
Titan Pharmaceuticals, Inc.

Conclusions and Strategic Implications

First Conclusion
Second Conclusion
Third Conclusion
Fourth Conclusion
Fifth Conclusion
Sixth Conclusion
Seventh Conclusion

Glossary

Company Directory

List of Exhibits

Table 1-1: Estimated Market Sizes for the Top Five Applications Segments for Neurotherapeutics in the Major World Healthcare Markets, 2001-2009
Table 1-2: Estimated Market Sizes for the Geographic Segments for Neurotherapeutics in the Major World Healthcare Markets, 2001-2009
Table 4-1: Known Genetic Alternation in Neurologic Neoplasms
Table 4-2: Active Clinical Trials Involving Alzheimer’s Disease and Dementia
Table 5-1: The Potential for Neurotherapeutics in the Seven Major World Healthcare Markets, 2001-2010
Table 5-2: The Potential for Neurotherapeutics in the United States by Application, 2001-2010
Table 5-3: The Potential for Neurotherapeutics in France by Application, 2001-2010
Table 5-4: The Potential for Neurotherapeutics in Germany by Application, 2001-2010
Table 5-5: The Potential for Neurotherapeutics in Italy by Application, 2001-2010
Table 5-6: The Potential for Neurotherapeutics in Spain by Application, 2001-2010
Table 5-7: The Potential for Neurotherapeutics in the United Kingdom by Application, 2001-2010
Table 5-8: The Potential for Neurotherapeutics in Japan by Application, 2001-2010
Table 5-9: The Potential for Neurotherapeutics in the Major World Healthcare Markets by Application 2001-2010
Table 5-10: The Potential for Alzheimer’s Disease/Dementia Therapeutics in the Major World Healthcare Markets 2001-2010
Figure 1-1: Incidence of Major Neurologic Diseases in the Major World Healthcare Markets, 2001-2010
Figure 1-2: The Total Market for Neurotherapeutics in the Major World Healthcare Markets, 2001-2010
Figure 1-3: Growth Rates in the World’s Seven Major Neurotherapeutics Markets by
Application, 2001-2009
Figure 1-4: Growth Rates in the World’s Seven Major Neurotherapeutics Markets by Geographic Region, 2001-2009
Figure 1-5: Composition of the Markets for Neurotherapeutics by Applications Segment, 2002 and 2010
Figure 1-6: Composition of the Markets for Neurotherapeutics by Geographic Segment, 2002 and 2010
Figure 4-1: Genes Associated with Neurologic Diseases and Disorders: Chromosomes 1-4
Figure 4-2: Genes Associated with Neurologic Diseases and Disorders: Chromosomes 5-8
Figure 4-3: Genes Associated with Neurologic Diseases and Disorders: Chromosomes 9-12
Figure 4-4: Genes Associated with Neurologic Diseases and Disorders: Chromosomes 13-16
Figure 4-5: Genes Associated with Neurologic Diseases and Disorders: Chromosomes 17-20
Figure 4-6: Genes Associated with Neurologic Diseases and Disorders: Chromosomes 21, 22, X, and Y
Figure 5-1: Growth Rates in Neurotherapeutics Potential for the Seven Major
World Healthcare Markets, 2001-2010
Figure 5-2: Distribution of the Estimated Market Potential for Neurotherapeutics in the Seven Major World Healthcare Markets, 2002
Figure 5-3: Growth Rates in Neurotherapeutics Market Opportunities 2001-2010
Figure 5-4: Distribution of the Estimated Market Potential for Neurotherapeutics in the Seven Major World Healthcare Markets by Application, 2002

Abstract

This report on Alzheimer’s disease represents selections from the larger market research study on neurotherapeutic drugs published by Kalorama Information in August 2002. The full study looked at the entire range of non-psychiatric neurological diseases and their treatments in the top seven world health markets. Here we present those parts of that study that are germane to Alzheimer’s disease.

In addition to the relevant selections, which are indicated on the Table of Contents and List of Exhibits in bold face with page numbers, we have also included the following in this report:

The complete Executive Summary from the full study;
Discussion of promising cutting-edge technologies and treatments with potentially broad application not limited to Alzheimer’s;
Top-level market numbers on the total worldwide market for neurotherapeutic drugs;
The Conclusions and Strategic Implications from the full study;
Appendix A: Glossary of Terms; and
Appendix B: Company Directory

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.